Top ▲

MMP9

Click here for help

Immunopharmacology Ligand target has curated data in GtoImmuPdb

Target id: 1633

Nomenclature: MMP9

Family: M10: Matrix metallopeptidase

Gene and Protein Information Click here for help
Species TM AA Chromosomal Location Gene Symbol Gene Name Reference
Human - 707 20q12-q13 MMP9 matrix metallopeptidase 9
Mouse - 730 2 H1-H2 Mmp9 matrix metallopeptidase 9
Rat - 708 3q42 Mmp9 matrix metallopeptidase 9
Previous and Unofficial Names Click here for help
GELB | gelatinase B | B/MMP9 | CLG4B | matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase)
Database Links Click here for help
Specialist databases
MEROPS M10.004 (Hs)
Other databases
BRENDA
CATH/Gene3D
ChEMBL Target
DrugBank Target
Ensembl Gene
Entrez Gene
Human Protein Atlas
KEGG Enzyme
KEGG Gene
OMIM
Orphanet
Pharos
RefSeq Nucleotide
RefSeq Protein
UniProtKB
Wikipedia
Selected 3D Structures Click here for help
Image of receptor 3D structure from RCSB PDB
Description:  Structure determination of a potent, selective antibody inhibitor of human MMP9 (GS-5745 bound to MMP-9).
PDB Id:  5TH9
Ligand:  andecaliximab
Resolution:  2.99Å
Species:  Human
References:  2
Enzyme Reaction Click here for help
EC Number: 3.4.24.35

Download all structure-activity data for this target as a CSV file go icon to follow link

Inhibitors
Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Value Parameter Reference
compound 1a [PMID: 15055993] Small molecule or natural product Primary target of this compound Hs Inhibition 10.2 pKi 12
pKi 10.2 (Ki 6x10-11 M) [12]
SL422 Small molecule or natural product Click here for species-specific activity table Hs Inhibition 9.1 pKi 17
pKi 9.1 (Ki 9x10-10 M) [17]
compound 29e [PMID: 23631440] Small molecule or natural product Click here for species-specific activity table Hs Inhibition 8.8 pKi 7
pKi 8.8 (Ki 1.5x10-9 M) [7]
(R)-ND-336 Small molecule or natural product Click here for species-specific activity table Hs Inhibition 7.7 pKi 14
pKi 7.7 (Ki 1.9x10-8 M) [14]
SB-3CT Small molecule or natural product Click here for species-specific activity table Hs Inhibition 6.2 pKi 5
pKi 6.2 (Ki 6x10-7 M) [5]
AZD6605 Small molecule or natural product Primary target of this compound Click here for species-specific activity table Immunopharmacology Ligand Hs Inhibition 8.7 pIC50 13
pIC50 8.7 (IC50 2x10-9 M) [13]
marimastat Small molecule or natural product Click here for species-specific activity table Ligand has a PDB structure Hs Inhibition 8.5 pIC50 16
pIC50 8.5 (IC50 3x10-9 M) [16]
AZD1236 Small molecule or natural product Primary target of this compound Click here for species-specific activity table Immunopharmacology Ligand Hs Inhibition 8.4 pIC50 3
pIC50 8.4 (IC50 4.5x10-9 M) [3]
CGS-27023A Small molecule or natural product Click here for species-specific activity table Ligand has a PDB structure Hs Inhibition 8.3 pIC50 15
pIC50 8.3 (IC50 4.8x10-9 M) [15]
ilomastat Small molecule or natural product Click here for species-specific activity table Ligand has a PDB structure Hs Inhibition 7.8 pIC50 10
pIC50 7.8 (IC50 1.5x10-8 M) [10]
Inhibitor Comments
SL422 is a broad-spectrum inhibitor of MMP enzymes [17].
Antibodies
Key to terms and symbols Click column headers to sort
Antibody Sp. Action Value Parameter Reference
andecaliximab Peptide Primary target of this compound Immunopharmacology Ligand Hs Binding 9.7 pIC50 11
pIC50 9.7 (IC50 2.18x10-10 M) [11]
Immunopharmacology Comments
Mucosal up-regulation of MMP-9 correlates with the severity of inflammation in ulcerative colitis, and may be responsible for the mucosal damage in active ulcerative colitis [9].
Immuno Process Associations
Immuno Process:  Inflammation
GO Annotations:  Associated to 4 GO processes
GO:0002687 positive regulation of leukocyte migration ISO
GO:0043312 neutrophil degranulation TAS
GO:0150077 regulation of neuroinflammatory response TAS
click arrow to show/hide IEA associations
GO:0050900 leukocyte migration IEA
Immuno Process:  Immune system development
GO Annotations:  Associated to 1 GO processes
GO:0030225 macrophage differentiation TAS
Immuno Process:  Cytokine production & signalling
GO Annotations:  Associated to 5 GO processes
GO:0019221 cytokine-mediated signaling pathway TAS
GO:0034612 response to tumor necrosis factor IEP
GO:0071345 cellular response to cytokine stimulus IEP
GO:0071347 cellular response to interleukin-1 IEP
GO:0071356 cellular response to tumor necrosis factor IEP
Immuno Process:  Cellular signalling
GO Annotations:  Associated to 1 GO processes
GO:0043312 neutrophil degranulation TAS
Immuno Process:  Immune regulation
GO Annotations:  Associated to 2 GO processes
GO:0002687 positive regulation of leukocyte migration ISO
GO:0150077 regulation of neuroinflammatory response TAS
Immuno Process:  Chemotaxis & migration
GO Annotations:  Associated to 2 GO processes, IEA only
GO:0002687 positive regulation of leukocyte migration ISO
click arrow to show/hide IEA associations
GO:0050900 leukocyte migration IEA
Immuno Disease Associations
Disease Name:  Multiple sclerosis
Disease Synonyms:  no synonynms
Comment:  MMP9 is upregulated in cerebrospinal fluid (CSF), blood and brain tissue of MS patients, can be a useful biomarker and expression level is reduced in response to MS treatment with interferon beta.
Disease X-refs:  Disease Ontology: DOID:2377
OMIM: 126200
Orphanet: ORPHA802
References:  1,4,18
Disease Name:  Irritable bowel syndrome
Disease Synonyms:  no synonynms
Comment:  MMP9 is suggested to be implicated in fistula formation in IBD. Upregulated mucosal MMP9 expression correlates with disease severity. MMP9 selective inhibitors are in development for the treatment of IBD.
Disease X-refs:  Disease Ontology: DOID:9778
References:  8-9,11
Disease Name:  Asthma
Disease Synonyms:  no synonynms
Comment:  MMP2 and MMP9 can promote the egress of inflammatory cells into airway lumen, suggesting a protective anti-inflammatory role in asthma. MMP2/MMP9 gelatinolytic activity is elevated in the sputum of asthmatic patients.
Disease X-refs:  Disease Ontology: DOID:2841
OMIM: 600807
References:  6
Clinically-Relevant Mutations and Pathophysiology Click here for help
Disease:  Intervertebral disc disease; IDD
Disease Ontology: DOID:9321
OMIM: 603932
Disease:  Metaphyseal anadysplasia 2; MANDP2
Synonyms: Metaphyseal anadysplasia [Orphanet: ORPHA1040]
OMIM: 613073
Orphanet: ORPHA1040

References

Show »

1. Anthony DC, Ferguson B, Matyzak MK, Miller KM, Esiri MM, Perry VH. (1997) Differential matrix metalloproteinase expression in cases of multiple sclerosis and stroke. Neuropathol Appl Neurobiol., 23 (5): 406-15. [PMID:9364466]

2. Appleby TC, Greenstein AE, Hung M, Liclican A, Velasquez M, Villaseñor AG, Wang R, Wong MH, Liu X, Papalia GA et al.. (2017) Biochemical characterization and structure determination of a potent, selective antibody inhibitor of human MMP9. J. Biol. Chem., 292 (16): 6810-6820. [PMID:28235803]

3. AstraZeneca. AZD1236. Accessed on 31/10/2014. Modified on 31/10/2014. Open Innovation, http://openinnovation.astrazeneca.com/what-we-offer/compound/azd1236/

4. Benesová Y, Vasku A, Novotná H, Litzman J, Stourac P, Beránek M, Kadanka Z, Bednarík J. (2009) Matrix metalloproteinase-9 and matrix metalloproteinase-2 as biomarkers of various courses in multiple sclerosis. Mult Scler., 15 (3): 316-22. [PMID:19153173]

5. Brown S, Bernardo MM, Li Z-H, Kotra LP, Tanaka Y, Fridman R, Mobashery S. (2000) Potent and Selective Mechanism-Based Inhibition of Gelatinases. J. Am. Chem. Soc., 122: 6799-6800.

6. Cataldo D, Munaut C, Noël A, Frankenne F, Bartsch P, Foidart JM, Louis R. (2000) MMP-2- and MMP-9-linked gelatinolytic activity in the sputum from patients with asthma and chronic obstructive pulmonary disease. Int. Arch. Allergy Immunol., 123 (3): 259-67. [PMID:11112863]

7. Jin Y, Roycik MD, Bosco DB, Cao Q, Constantino MH, Schwartz MA, Sang QX. (2013) Matrix metalloproteinase inhibitors based on the 3-mercaptopyrrolidine core. J. Med. Chem., 56 (11): 4357-73. [PMID:23631440]

8. Kirkegaard T, Hansen A, Bruun E, Brynskov J. (2004) Expression and localisation of matrix metalloproteinases and their natural inhibitors in fistulae of patients with Crohn's disease. Gut, 53 (5): 701-9. [PMID:15082589]

9. Lakatos G, Sipos F, Miheller P, Hritz I, Varga MZ, Juhász M, Molnár B, Tulassay Z, Herszényi L. (2012) The behavior of matrix metalloproteinase-9 in lymphocytic colitis, collagenous colitis and ulcerative colitis. Pathol. Oncol. Res., 18 (1): 85-91. [PMID:21678108]

10. Ma D, Wu W, Yang G, Li J, Li J, Ye Q. (2004) Tetrahydroisoquinoline based sulfonamide hydroxamates as potent matrix metalloproteinase inhibitors. Bioorg. Med. Chem. Lett., 14 (1): 47-50. [PMID:14684295]

11. Marshall DC, Lyman SK, McCauley S, Kovalenko M, Spangler R, Liu C, Lee M, O'Sullivan C, Barry-Hamilton V, Ghermazien H et al.. (2015) Selective Allosteric Inhibition of MMP9 Is Efficacious in Preclinical Models of Ulcerative Colitis and Colorectal Cancer. PLoS ONE, 10 (5): e0127063. [PMID:25961845]

12. Moriyama H, Tsukida T, Inoue Y, Yokota K, Yoshino K, Kondo H, Miura N, Nishimura S. (2004) Azasugar-based MMP/ADAM inhibitors as antipsoriatic agents. J. Med. Chem., 47 (8): 1930-8. [PMID:15055993]

13. MRC. AZD6605 Matrix metallopeptidase 13 (MMP13) inhibitor. Accessed on 28/10/2014. Modified on 28/10/2014. MRC/AstraZeneca: Mechanisms of Disease Call, http://webarchive.nationalarchives.gov.uk/20120104105854/http://www.mrc.ac.uk/consumption/groups/public/documents/content/mrc008371.pdf

14. Nguyen TT, Ding D, Wolter WR, Pérez RL, Champion MM, Mahasenan KV, Hesek D, Lee M, Schroeder VA, Jones JI et al.. (2018) Validation of Matrix Metalloproteinase-9 (MMP-9) as a Novel Target for Treatment of Diabetic Foot Ulcers in Humans and Discovery of a Potent and Selective Small-Molecule MMP-9 Inhibitor That Accelerates Healing. J. Med. Chem., 61 (19): 8825-8837. [PMID:30212201]

15. Nuti E, Casalini F, Santamaria S, Gabelloni P, Bendinelli S, Da Pozzo E, Costa B, Marinelli L, La Pietra V, Novellino E et al.. (2011) Synthesis and biological evaluation in U87MG glioma cells of (ethynylthiophene)sulfonamido-based hydroxamates as matrix metalloproteinase inhibitors. Eur J Med Chem, 46 (7): 2617-29. [PMID:21514700]

16. Rasmussen HS, McCann PP. (1997) Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat. Pharmacol. Ther., 75 (1): 69-75. [PMID:9364582]

17. Xue CB, Voss ME, Nelson DJ, Duan JJ, Cherney RJ, Jacobson IC, He X, Roderick J, Chen L, Corbett RL et al.. (2001) Design, synthesis, and structure-activity relationships of macrocyclic hydroxamic acids that inhibit tumor necrosis factor alpha release in vitro and in vivo. J. Med. Chem., 44 (16): 2636-60. [PMID:11472217]

18. Yong VW, Zabad RK, Agrawal S, Goncalves Dasilva A, Metz LM. (2007) Elevation of matrix metalloproteinases (MMPs) in multiple sclerosis and impact of immunomodulators. J Neurol Sci., 259: 79-84. [PMID:17382965]

How to cite this page

M10: Matrix metallopeptidase: MMP9. Last modified on 28/07/2020. Accessed on 25/10/2020. IUPHAR/BPS Guide to PHARMACOLOGY, http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1633.